Community Oncology Alliance (COA) submitted formal comments to CMS in support of proposed changes to the 340B Drug Discount Program and site-neutral paymnts put forward in the Hospital Outpatient Prospective Payment (HOPPS) rule. However, they also submitted comments warning against proposals to introduce new third-party middlemen to the Part B system.
The Community Oncology Alliance (COA) submitted formal comments to CMS in support of the agency's proposed additional changes to the 340B Drug Discount Program. They also voiced support for the site-neutral payments proposed in the Hospital Outpatient Prospective Payment (HOPSS) rule for 2019, which they say will address "tremendous Medicare Part B spending increases that have resulted from the growing shift of care from independent community practices to hospital outpatient departments."
However, COA did caution against proposals for introducing new third-party middlemen to the Part B system, saying it would have a negative impact on patient care.
Read the comments in full here.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More